|NCPE Assessment Process Complete
|For the prevention of stroke and systemic embolism in atrial fibrillation
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended
Following the NCPE pharmacoeconomic assessment (August 2011) the manufacturer reduced the price of dabigatran. At this revised price we now consider dabigatran cost effective for this indication.